The current pandemic has led to temporarily increased drug sales for most influential Bio/Pharma companies in Q1 of this year. Brokers recognise that these sales increase sales when contrasted with those anticipated for Q1 2020 due to Covid-19-related purchases, as individuals stockpiled in preparation for decreased medical access in the lockdown.

Nevertheless, companies with fewer marketed drugs relying predominantly on the Covid-19 asset in their pipeline are gambling on the drug going to market, while other prominent Bio/Pharma companies may prevail in the long-term due to their diverse drug portfolios. Read more here.